Skip to main content

Table 7 Effect of genotypes on platelet aggregation of both pre- and post-aspirin treatment (%)

From: Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients

  Pre-aspirin aggregation Platelet Post-aspirin aggregation Platelet
AA- induced ADP-induced AA- induced ADP-induced
COX-1 (rs1236913)
 CC (n = 765) 88.4 ± 15.7 89.2 ± 14.7 18.9 ± 9.2 66.8 ± 12.8
 CT + TT (n = 85) 89.2 ± 14.6 89.7 ± 13.2 19.4 ± 8.8 67.5 ± 10.8
P-value 0.65 0.73 0.63 0.57
COX-1 (rs3842787)
 CC (n = 675) 87.9 ± 16.3 88.6 ± 14.7 19.2 ± 8.4 67.7 ± 11.5
 CT + TT (n = 175) 89.7 ± 13.6 90.1 ± 15.8 19.0 ± 7.8 66.6 ± 12.3
P-value 0.15 0.21 0.86 0.28
COX-2 (rs689466)
 AA (n = 243) 88.9 ± 16.3 89.2 ± 12.8 20.1 ± 10.2 66.8 ± 13.2
 AG + GG (n = 607) 89.7 ± 14.1 90.3 ± 16.9 18.9 ± 9.8 67.2 ± 11.5
P-value 0.51 0.36 0.12 0.67
COX-2 (rs20417)
 GG (n = 583) 87.9 ± 15.4 88.3 ± 15.2 18.2 ± 8.6 65.9 ± 13.4
 GC + CC (n = 267) 89.7 ± 15.7 89.6 ± 14.6 19.5 ± 9.6 67.1 ± 14.9
P-value 0.13 0.26 0.34 0.07
TXAS1 (rs194149)
 GG (n = 265) 90.2 ± 16.7 89.4 ± 12.9 19.1 ± 7.6 67.9 ± 12.2
 AG + AA (n = 585) 88.6 ± 17.5 88.9 ± 15.6 18.7 ± 6.7 68.4 ± 13.8
P-value 0.22 0.64 0.47 0.64
TXAS1 (rs2267679)
 TT (n = 700) 88.9 ± 17.7 89.1 ± 14.9 19.3 ± 8.9 66.5 ± 14.2
 CC + CT (n = 150) 90.3 ± 15.6 90.2 ± 16.4 18.4 ± 8.2 67.9 ± 15.5
P-value 0.33 0.44 0.19 0.31
TXAS1 (rs41708)
 GG (n = 509) 88.8 ± 13.6 88.9 ± 15.2 18.8 ± 7.2 68.1 ± 12.5
 TT + GT (n = 341) 90.1 ± 17.8 89.4 ± 13.8 19.3 ± 8.4 67.6 ± 11.1
P-value 0.18 0.63 0.41 0.54
P2Y1 (rs701265)
 AA (n = 457) 88.9 ± 15.3 88.7 ± 16.1 19.2 ± 7.7 67.8 ± 13.2
 AG + GG (n = 393) 89.6 ± 17.7 89.5 ± 14.2 18.4 ± 8.1 68.5 ± 14.4
P-value 0.54 0.42 0.15 0.44
P2Y1 (rs1439010)
 AA (n = 460) 90.3 ± 16.8 90.1 ± 16.6 19.1 ± 6.8 66.9 ± 13.6
 AG + GG (n = 390) 88.5 ± 15.2 89.0 ± 15.3 18.7 ± 7.4 67.7 ± 12.2
P-value 0.11 0.31 0.42 0.34
P2Y1 (rs1371097)
 CC (n = 479) 89.2 ± 15.6 87.9 ± 16.2 18.8 ± 7.2 68.1 ± 12.5
 TT + CT (n = 371) 88.6 ± 14.1 89.2 ± 15.6 19.3 ± 8.4 67.6 ± 11.1
P-value 0.57 0.21 0.31 0.62
P2Y12 (rs16863323)
 CC (n = 206) 87.9 ± 16.4 88.8 ± 16.4 18.9 ± 7.6 67.2 ± 13.2
 TT + CT (n = 644) 89.9 ± 18.7 89.2 ± 14.5 18.7 ± 8.2 67.8 ± 12.3
P-value 0.14 0.76 0.73 0.51
P2Y12 (rs9859538)
 GG (n = 626) 88.5 ± 16.5 88.9 ± 14.3 18.4 ± 8.7 66.7 ± 11.
 AG + AA (n = 224) 89.9 ± 16.8 90.1 ± 16.7 19.1 ± 7.9 67.5 ± 13.6
P-value 0.28 0.31 0.33 0.41
GPIIIa (rs2317676)
 AA (n = 536) 89.5 ± 15.2 87.9 ± 13.7 19.2 ± 8.2 68.3 ± 14.2
 AG + GG (n = 314) 88.2 ± 15.7 89.4 ± 17.8 18.5 ± 7.1 67.4 ± 13.3
P-value 0.32 0.23 0.26 0.36
GPIIIa (rs11871251)
 AA (n = 267) 89.2 ± 12.6 89.8 ± 16.6 19.4 ± 8.7 66.9 ± 15.7
 AG + GG (n = 583) 88.6 ± 14.9 89.2 ± 14.3 18.6 ± 7.5 67.5 ± 14.4
P-value 0.53 0.56 0.19 0.49
High-risk interactive genotypes
 Yes (n = 147) 90.6 ± 18.4 90.3 ± 17.5 30.3 ± 9.2 79.9 ± 12.2
 No (n = 703) 88.8 ± 16.7 88.7 ± 13.8 15.6 ± 6.8 62.3 ± 11.1
P-value 0.28 0.27 < 0.001 < 0.001